J Cancer 2020; 11(6):1555-1567. doi:10.7150/jca.37529 This issue Cite

Review

Progress in Animal Models of Pancreatic Ductal Adenocarcinoma

Kaiwen Kong1*, Meng Guo2*, Yanfang Liu3✉, Jianming Zheng1✉

1. Pathology Department of Changhai Hospital, Second Military Medical University
2. Institute of Organ Transplantation, Changzheng Hospital, Second Military Medical University, Shanghai, China; National Key Laboratory of Medical Immunology &Institute of Immunology, Second Military Medical University
3. Pathology Department of Changhai Hospital, Second Military Medical University; National Key Laboratory of Medical Immunology &Institute of Immunology, Second Military Medical University
* Kaiwen Kong and Meng Guo are co-first authors.

Citation:
Kong K, Guo M, Liu Y, Zheng J. Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. J Cancer 2020; 11(6):1555-1567. doi:10.7150/jca.37529. https://www.jcancer.org/v11p1555.htm
Other styles

File import instruction

Abstract

As a common gastrointestinal tumor, the incidence of pancreatic cancer has been increasing in recent years. The disease shows multi-gene, multi-step complex evolution from occurrence to dissemination. Furthermore, pancreatic cancer has an insidious onset and an extremely poor prognosis, so it is difficult to obtain cinical specimens at different stages of the disease, and it is, therefore, difficult to observe tumorigenesis and tumor development in patients with pancreatic cancer. At present, no standard protocols stipulate clinical treatment of pancreatic cancer, and the benefit rate of new targeted therapies is low. For this reason, a well-established preclinical model of pancreatic cancer must be established to allow further exploration of the occurrence, development, invasion, and metastasis mechanism of pancreatic cancer, as well as to facilitate research into new therapeutic targets. A large number of animal models of pancreatic cancer are currently available, including a cancer cell line-based xenograft, a patient-derived xenograft, several mouse models (including transgenic mice), and organoid models. These models have their own characteristics, but they still cannot perfectly predict the clinical outcome of the new treatment. In this paper, we present the distinctive features of the currently popular pancreatic cancer models, and discuss their preparation methods, clinical relations, scientific purposes and limitations.


Citation styles

APA
Kong, K., Guo, M., Liu, Y., Zheng, J. (2020). Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. Journal of Cancer, 11(6), 1555-1567. https://doi.org/10.7150/jca.37529.

ACS
Kong, K.; Guo, M.; Liu, Y.; Zheng, J. Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. J. Cancer 2020, 11 (6), 1555-1567. DOI: 10.7150/jca.37529.

NLM
Kong K, Guo M, Liu Y, Zheng J. Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. J Cancer 2020; 11(6):1555-1567. doi:10.7150/jca.37529. https://www.jcancer.org/v11p1555.htm

CSE
Kong K, Guo M, Liu Y, Zheng J. 2020. Progress in Animal Models of Pancreatic Ductal Adenocarcinoma. J Cancer. 11(6):1555-1567.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image